InSightec begin post-marketing ExAblate trial
This article was originally published in Clinica
Executive Summary
Israel-based InSightec is conducting a post-marketing surveillance study evaluating the benefit of is ExAblate 2000 system therapy in treating African-American women with uterine fibroids. The study is a condition of the US FDA's approval for ExAblate 2000, granted in October 2004.